Although EGFR is a well-established target for nanoparticle-based drug delivery in NSCLC [92], the recent literature did not reveal studies that specifically integrated EGFR-targeted nanoparticles with melittin delivery. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.